Classifying hepatitis B therapies with insights from covalently closed circular DNA dynamics
Related Experiment Video
Updated: Jul 8, 2025

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection
Published on: November 7, 2018
1Key Laboratory of Molecular Biology on Infectious Diseases, Ministry of Education, Chongqing Medical University, Chongqing, 400016, China.
Insights
Achieving a functional cure for chronic hepatitis B (CHB) requires reducing hepatitis B virus (HBV) covalently closed circular DNA (cccDNA). This review classifies HBV treatment strategies by their impact on cccDNA dynamics, advocating for combination therapy to enhance cure rates.
Area of Science:
- Hepatology
- Virology
- Systems Biology
Background:
- Functional cure for chronic hepatitis B (CHB) is limited with current therapies.
- Reducing covalently closed circular DNA (cccDNA) is essential for CHB functional cure.
- Understanding cccDNA dynamics is crucial for developing effective anti-HBV strategies.
Purpose of the Study:
- To elucidate the HBV replication cycle using a systems thinking approach.
- To rationalize the classification of anti-HBV treatment strategies based on cccDNA dynamics.
- To propose a combined therapeutic approach for significant cccDNA reduction.
Main Methods:
- Systems thinking analysis of the HBV replication cycle.
- Classification of existing anti-HBV strategies based on their effect on cccDNA.
- Review of factors influencing cccDNA dynamics during treatment.
Main Results:
- HBV replication cycle fundamentals elucidated through systems thinking.
- Anti-HBV strategies categorized into two distinct groups based on cccDNA impact.
- A framework for understanding cccDNA dynamics during CHB treatment.
Conclusions:
- Combination therapy is advocated to significantly reduce cccDNA levels.
- A systems approach provides a rational basis for classifying and combining anti-HBV treatments.
- Enhanced functional cure rates for CHB are achievable with optimized therapeutic strategies.
Abstract:
The achievement of a functional cure for chronic hepatitis B (CHB) remains limited to a minority of patients treated with currently approved drugs. The primary objective in developing new anti-HBV drugs is to enhance the functional cure rates for CHB. A critical prerequisite for the functional cure of CHB is a substantial reduction, or even eradication of covalently closed circular DNA (cccDNA). Within this context, the changes in cccDNA levels during treatment become as a pivotal concern. We have previously analyzed the factors influencing cccDNA dynamics and introduced a preliminary classification of hepatitis B treatment strategies based on these dynamics. In this review, we employ a systems thinking perspective to elucidate the fundamental aspects of the HBV replication cycle and to rationalize the classification of treatment strategies according to their impact on the dynamic equilibrium of cccDNA. Building upon this foundation, we categorize current anti-HBV strategies into two distinct groups and advocate for their combined use to significantly reduce cccDNA levels within a well-defined timeframe.
More Related Videos
09:35Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Related Concept Videos
Retrovirus Life Cycles
Leaky Scanning
Retroviruses
Lytic Cycle of Bacteriophages